What Is Thrombosis?
Acute Ischemic Stroke (AIS):
Deadly, Disabling, Costly and Undertreated
There is also evidence of increasing incidence of stroke in younger
individuals (under 55).
Current AIS treatments reach <15% of all patients and have significant limitations
The limitations of current acute revascularization treatments in AIS mean that the vast majority of patients do not receive any acute treatment. A safe, effective, reversible drug will greatly expand access to acute revascularization treatment. Restoring blood flow quickly is the only medical intervention that is proven to improve outcomes in AIS.
Basking’s BB-031 is a first-in-class RNA aptamer targeting von Willebrand Factor (vWF), a key driver of the blood clotting process. It is specifically designed to have a rapid-onset, be short-acting and reversible.
BB-031 is engineered to be safer and more effective, and capable of reopening blocked arteries beyond the therapeutic time window of standard of care, thus increasing the eligibility of the AIS patient population for acute revascularization.
Compelling Nonclinical Model Data
BB-031 successfully restored blood flow in middle cerebral artery occlusion (MCAO) when administered 6 hours following stroke onset
Stroke volume measures the percentage of brain without adequate oxygen supply and is an important prognostic indicator of extent of recovery
BB-025 demonstrated reversal of BB-031 5 minutes post-administration in multiple small and large animal models
The Path Forward
A Phase II clinical trial in ischemic stroke patients will be initiated in 2024.
Contact us if you have an interest in participating as a trial investigator.